Early Mouse Study: CB1400 Prevents Tumor Growth/Synergistic

[Barb73]

http://www.medicalnewstoday.com/articles/112050.php

Excerpt from article:

. . . . . . . . .

Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models.

Chairman of Canopus BioPharma, Dr. Patrick Prendergast, stated, "We at Canopus are encouraged with the discovery of this new use for CB1400 to increase efficacy and reduce toxicity issues associated with conventional chemotherapeutic agents."

CB1400, a former schistosomal drug, is currently in phase II clinical development as an anti-mucositis preventative agent in patients receiving radio- and/or chemotherapy treatment. Current anti-mucositis drugs have shown tumor-protective properties. For this reason CB1400 was evaluated by Canopus to determine its effect on tumor growth.

In work carried out by the Harvard School of Dental Medicine, Boston, on behalf of Canopus BioPharma, it was confirmed that CB1400 as a single agent significantly reduces tumor growth. In an initial study, tumor growth was inhibited by 48.8% in mice treated with cisplatin, the most commonly used chemotherapy drug. CB1400 alone showed 62.3% tumor growth inhibition while the combination of both compounds further increased inhibition to 69.6%, thus confirming a synergistic effect between cisplatin and CB1400. In addition, there was no evidence of toxicity based on observations of survival and weight change in the mice and there was no evidence that CB1400 protected the tumor.

Cisplatin is a platinum-containing chemotherapeutic drug, administered by IV injection which has been used for more than 30 years to treat various forms of cancer. Enhanced efficacy with CB1400 may prevent the development of drug resistance that is common with cisplatin.

In a similar study, tumor growth was inhibited by 61% in mice treated with cetuximab (Erbitux) alone. An almost 30% increase in efficacy was observed with the addition of CB1400 to cetuximab, increasing tumor inhibition to 89.4%, confirming a synergistic effect of combining the two anti-tumor drugs. Similar to the cisplatin study, there was no significant difference in mean weight or survival between the groups of mice; and no toxicity was observed in this study.

Cetuximab is a chimeric monoclonal antibody, an epidermal growth factor receptor inhibitor used as a chemotherapeutic agent, administered by IV injection for the treatment of various cancers. Enhancing the efficacy of cetuximab may have potential in treating patients no longer responding to traditional chemotherapy.

. . . . . . . . .

(Medical News Today, Lung Cancer, Cancer/Oncology, June 20, 2008)

Disclaimer:

The information contained in these articles may or may not be in agreement with my own opinions. They are not posted as medical advice of any kind.

[CaroleHammett]

"...An almost 30% increase in efficacy was observed with the addition of CB1400 to cetuximab, increasing tumor inhibition to 89.4%, confirming a synergistic effect of combining the two anti-tumor drugs. Similar to the cisplatin study, there was no significant difference in mean weight or survival between the groups of mice; and no toxicity was observed in this study...."

Almost makes me wish I was a mouse!

Carole

[Barb73]

Carole,

Today, I needed that laugh. Thank you.

Barbara

[CaroleHammett]

And I needed your "four hour" laugh, too, so we're not only even, but we've made each others day... which is what it's all about, right?

Affectionately, Carole

[Barb73]

Yes, Carole, that is what it is all about.

Laughter has always been and still is beneficial in our lives.

It releases something...endorphins? or is that the runner's (high) hormone?

Sending lots of caring and best thoughts,

Barbara